Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA  by Yi, Lun-Zhao et al.
FEBS Letters 580 (2006) 6837–6845Plasma fatty acid metabolic proﬁling and biomarkers of type 2
diabetes mellitus based on GC/MS and PLS-LDA
Lun-Zhao Yia, Jun Heb, Yi-Zeng Lianga,*, Da-Lin Yuana, Foo-Tim Chauc
a Research Center of Modernization of Chinese Medicines, Central South University, Changsha 410083, PR China
b Pharmacogenetics Institute of Central South University, Changsha 410078, PR China
c Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong
Received 19 October 2006; accepted 16 November 2006
Available online 27 November 2006
Edited by Sandro SonninoAbstract Metabolic proﬁling has increasingly been used as a
probe in disease diagnosis and pharmacological analysis. Herein,
plasma fatty acid metabolic proﬁling including non-esteriﬁed
fatty acid (NEFA) and esteriﬁed fatty acid (EFA) was investi-
gated using gas chromatography/mass spectrometry (GC/MS)
followed by multivariate statistical analysis. Partial least
squares-linear discrimination analysis (PLS-LDA) model was
established and validated to pattern discrimination between type
2 diabetic mellitus (DM-2) patients and health controls, and to
extract novel biomarker information. Furthermore, the PLS-
LDA model visually represented the alterations of NEFA meta-
bolic proﬁles of diabetic patients with abdominal obesity in the
treated process with rosiglitazone. The GC/MS-PLS-LDA anal-
ysis allowed comprehensive detection of plasma fatty acid, en-
abling fatty acid metabolic characterization of DM-2 patients,
which included biomarkers diﬀerent from health controls and dy-
namic change of NEFA proﬁles of patients after treated with
medicine. This method might be a complement or an alternative
to pathogenesis and pharmacodynamics research.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Metabolomics has distinct advantages over other omics ap-
proaches in eﬃciently building knowledge of biological status
because intermediary metabolism is proximal to phenotype,
and because metabolites can be measured quantitatively and
comprehensively [1,2]. Based on the multivariate analysis of
complex biological proﬁles, metabolomics has successfully ap-
plied to many ﬁelds such as plant genotype discrimination [3–
5], toxicological screening [6] and disease diagnosis [7–10].
NMR is the most commonly used technique for metabolomics
because its advantages of being non-destructive, applicable toAbbreviations: DM-2, type 2 diabetes mellitus; EFA, esteriﬁed fatty
acid; NEFA, non-esteriﬁed fatty acid; PLS-LDA, partial least squares-
linear discrimination analysis; FBG, fasting blood glucose; LV, latent
variable
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doi:10.1016/j.febslet.2006.11.043intact biomaterials, and accessing intrinsically more informa-
tion rich in complex–mixture analyses, while it is diﬃcult to
accurate qualitative and quantitative analysis of metabolites
[11–14]. Gas chromatography/mass spectrometry (GC/MS) is
a relatively low cost alternative that provides high separation
eﬃciency to resolve the complex biological mixtures. This tech-
nique coupled with pattern recognition has been proved to be a
good choice for metabolite proﬁling of plant genotype [3].
Type 2 diabetes mellitus (DM-2) disease is a typical metab-
olism disorder disease [15]. There are predictions that DM-2
could increase worldwide to more than 250 million individuals
within the next decade or so. Despite this, we still are unclear
as to its causes and its optimal treatment. A number of studies
about this disease have demonstrated that diabetes mellitus is
directly associated with metabolism disorder of lipid, especially
fatty acids because they provide an important energy source as
nutrients, and also act as signaling molecules in various cellu-
lar processes, including insulin secretion and cardiovascular
risk [16–19]. Once diabetes develops, non-esteriﬁed fatty acid
(NEFA) plasma levels show a linear correlation with blood
glucose levels and hepatic glucose production, regardless of
whether the person is lean or obese [20–22]. Although there
are some publications associated with fatty acid and its rela-
tionship with type 2 diabetes mellitus, none of these involved
comprehensive quantitative analysis of NEFAs and esteriﬁed
fatty acids (EFAs), 3D discrimination model of DM-2 patients
and health controls [23].
Thiazolidinediones (TZDs) is a class of drugs which work to
lower the resistance to insulin in fat, liver and muscle cells and
also, by stopping abnormalities and dysfunctions in b-cells,
were proved to have the ability to release total free fatty acids
in plasma [24,25]. Fatty acid metabolic proﬁles of patients’
plasma will have some changes when treated with TZDs [26].
However, it is not known how each NEFA changed and which
increased signiﬁcantly in the process. Visually representing
those changes will not only help us to investigate the altera-
tions of marked metabolites, but also give us some guidance
to clinic treatment. Unfortunately, there are not any reports
about this research.
In this paper, we employed GC/MS technology in order to
study the comprehensive quantitative NEFA and EFA meta-
bolic proﬁling. Then, principal component analysis (PCA)
method was used to overview the distribution of all 123 human
plasma samples and try to classify the type 2 diabetic mellitus
(DM-2) patients and healthy persons (controls). In order to
visual represent the alterations of NEFA metabolic proﬁles
of type 2 diabetic patients treated with rosiglitazone, weblished by Elsevier B.V. All rights reserved.
Table 1
GC column temperature program
Start time
(min)
Rate
(C/min)
End time
(min)
Final
temperature (C)
Hold
time (min)
0 0 0 70 1
1 20 5 150 0
5 6 10 180 0
10 20 12 220 2
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nation analysis (PLS-LDA) method to construct a 3D visual
model which has good predictive power. Herein, we show
the beneﬁts of the model not only to discriminate the DM-2
and controls, but also visual represent the variances of metab-
olites when treated with rosiglitazone. Furthermore, the key
NEFAs (potential biomarkers) which have the most inﬂuence
on the separation between sample classes were found out by
the help of PLS-LDA model.2. Materials and methods
2.1. Sample collection
Human plasma samples were collected from 45 healthy adults (age
range was 24–78), 78 patients with DM-2 (age range was 26–67). All
type 2 diabetic patients were from the Xiangya Hospital of Hunan
of China with a fasting plasma glucose concentration above
7.0 mmol L1. Furthermore, we picked up 10 abdominal obesity pa-
tients with DM-2 to be treated with rosiglitazone (six women and four
men). Plasma samples of these 10 patients were collected at 0 (n = 10),
2(n = 5), 4(n = 7), 9(n = 8) and 14 weeks (n = 6) after treated with ros-
iglitazone. All clinical experiments were approved by Xiangya Institu-
tional Human Subjects Committee.2.2. Solvents and standards
Oleic acid (C18:1n-9, Purity: minimum 99.0%), oleic acid methyl ester
(C18:1n-9 methyl ester, Purity: minimum 99.0%), 11-octadecenoic acid
(C18:1n-7, Purity: minimum 99.0%), heptadecanoic acid (C17:0, Purity:
minimum 99.0%), linolenic acid (C18:3n-3, Purity: minimum 99.0%), c-
linolenic acid (C18:3n-6, Purity: minimum 99.0%), linoleic acid
(C18:2n-6, Purity: minimum 99.0%), palmitoleic acid (C16:1n-7, Purity:
minimum 99.0%) and heptadecanoic acid methyl ester (C17:0 methyl
ester, Purity: minimum 99.0%) were purchased from Sigma (St. Louis,
MO, USA). The solution 5% H2SO4/CH3OH was freshly prepared by
diluting H2SO4 (Purity: minimum 98.0%) by chromatographic grade
methanol, and 0.4 M KOH/CH3OH was freshly prepared in our labo-
ratory by dissolving a reagent grade KOH in methanol.2.3. Sample preparation
Each collected blood sample was immediately centrifuged at
3000 · g for 10 min and plasma was transferred into a clean Eppendorf
tube. The plasma samples were stored at 80 C until analysis. Ali-
quots (200 ll) of plasma were spiked with internal standard (I.S.)
working solution (25 ll C17:0 and 25 ll C17:0 methyl ester) and 2 ml
0.4 M KOH–CH3OH was added, vortex-mixed for 30 s and placed
at room temperature for 10 min, and then extracted with 2 ml of hex-
ane twice using a vortex mixer for 30 s. The hexane phase was the EFA
methyl esters, and this phase was evaporated to dryness under N2 gas.
After that, some anhydrous sodium sulfate were added to remove
traces of water and 2 ml 5% H2SO4–CH3OH was added to the residu-
ary phase of plasma, reacted at 70 C water bath for 30 min. Then, it
was extracted with 2 ml of hexane twice using a vortex mixer for 30 s
and the NEFA methyl esters were obtained. Samples were evaporated
to dryness under N2 gas. Hexane (100 ll) was added to each tube prior
to analysis.2.4. Gas chromatography–mass spectrometry
All GC–MS analyses were performed by a Shimadzu GC2010A
(Kyoto, Japan) gas chromatography instrument coupled to a
GCMS-QP2010 mass spectrometer (Compaq-Pro Linear data system,
class5K software). In the gas chromatographic system, a DB-WAX
capillary column (30 m · 0.25 mm I.D., ﬁlm thickness 0.25 lm) was
used. The GC column temperature program is shown in Table 1.
The total GC run time was 14 min. Inlet temperature was kept at
250 C. Helium carrier gas was used at a constant ﬂow rate of
1.0 ml min1. A sample of 1.0 ll was injected, the split ratio of the
injector being 1:50. Mass conditions were: ionization voltage, 70 eV;
ion source temperature, 200 C; full scan mode in the 30–450 l mass
ranges with 0.2 s/scan velocity.2.5. Feature selection
The general purpose of feature selection is to ﬁnd the best combina-
tion of features, which provides the best classiﬁcation result. The irrel-
evant variables that introduce noise should be eliminated. In this
study, the variance weights of individual variables were calculated to
obtain the best feature combination to discriminate the DM-2 and con-
trol. These weights were the ratio of between-class variance to within-
class variance for the training groups. For two classes, subscripts T and
C here denote the class of DM-2 patients and the class of health
controls, respectively. Then, the weight of the jth variable (j = 1,
2, . . . , 21) could be obtained using the following equation:
Weightj ¼
nCnT=n2
PnC
c¼1
PnT
t¼1
ðxcj  xtjÞ2
nC=n
PnC
c0¼1
PnC
c¼1
ðxc0j  xcjÞ2 þ nT=n
PnT
t0¼1
PnT
t¼1
ðxt0j  xtjÞ2
ðc or c0 ¼ 1; 2; . . . ; nc and t or t0 ¼ 1; 2; . . . ; nTÞ ð1Þ
Here nC and nT are the number in class C (health controls) and the
number in class T (DM-2 patients), respectively. It is obvious that
nC + nT = n. Subscripts c, c
0, t and t 0 denote the indices of the samples
in class C and T, respectively. Thus, xcj represents the value of the jth
variable of sample c.
2.6. Principal component analysis (PCA) of the GC–MS data
The autoscaled data of EFA and NEFA were analysed by PCA to
establish any ‘groupings’ with respect to type 2 diabetic patients and
health controls. A PCA model was constructed using all samples.
The scores plot of PC1 versus PC2 was examined for separation or
clusters relating to the two groups, DM-2 and control.
2.7. Prediction and application of model by partial least squares-linear
discrimination analysis (PLS-LDA)
As PCA indicated the presence of DM-2 and health controls separa-
tion, data were analysed by PLS-LDA with a view to establish whether
the separation between DM-2 and control was signiﬁcant by prediction
of class. PLS-LDA models were constructed to establish the signiﬁ-
cance of the diﬀerence of DM-2 and health controls. For the purpose
of cross-validation and due to the small number of samples, 10 valida-
tion PLS-LDA models were calculated excluding 25% of the samples
per class in each validation model. Class membership was predicted
using discrimination plane between two classes. Furthermore, the
determined PLS-LDA model was applied to visually represent the var-
iance of NEFA metabolic proﬁles of type 2 diabetic patients treated
with rosiglitazone.
2.8. Finding potential biomarkers
If the ﬁrst three PLS latent variables (LVs) were extracted to estab-
lish the LDA model, the equation of the discrimination plane could be
expressed as follows:
a1t1 þ a2t2 þ a3t3 ¼ c ð2Þ
where t1, t2 and t3 are the ﬁrst three LVs obtained by PLS decomposi-
tion, a1, a2, and a3 are the coeﬃcients of discrimination plane equation,
c is a constant. Eq. (2) can be written as matrix form:
Ta ¼ c ð3Þ
where T = [t1t2t3], a = [a1a2a3]
t, superscript ‘‘t’’ stands for transport.
As we know, each LVs ti is the linear combination of column vectors
of X [27], that is
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where X is the data matrix andH is the weight matrix obtained by PLS
decomposition.
Inserting Eq. (4) into Eq. (3),
XHa ¼ c ð5Þ
Let b = Ha, so
Xb ¼ c ð6Þ
Then, the plane equation expressed by PLS LVs (scores) was trans-
formed to that expressed by original variables. In the transformed
equation (Eq. (6)), the absolute values of coeﬃcients (b) can render
the inﬂuence of corresponding variables on separation between sample
classes. In turn, these compounds corresponding to these variables
might be likely candidates for biomarkers.3. Results and discussion
3.1. GC/MS proﬁles of plasma samples from DM-2 and health
controls
Human plasma fatty acids were divided into two groups,
EFA and NEFA. For most fatty acid analysis, only total plas-
ma fatty acids or several fatty acids are taken into account in
an experiment. Herein, we developed a two-step rapid method
for comprehensive proﬁling of NEFA and EFA using KOH–
CH3OH to methylate EFAs followed by H2SO4–CH3OH to
methylate NEFAs. Then, GC/MS was applied to components
isolation and detection. Method repeatability was evaluated by
the analysis of ﬁve replicates of solid sample. The RSD of peak
area ratios (analyte: I.S.) of 20 detected fatty acids in sample
replicates were estimated to be 2.95–15.60%. Intra-day accu-
racy and precision (each, n = 5) were evaluated as 4.17–
5.09% RSD, by analysis of quality control (QC) samples (25,
250, 2500 lM of C18:1n-9 methyl ester) at diﬀerent times dur-
ing the same day. Inter-day accuracy and precision were deter-
mined as 7.77–8.84% RSD, by repeated analysis of QC
samples over 5 consecutive days (n = 1 series per day). Further-
more, yields of the liquid–liquid extraction method and ester-
iﬁcation process were assessed using C18:1n-9 and C18:1n-9
methyl ester standards and obtained the reaction yields of
95.22 ± 2.53% (n = 5) and 96.96 ± 1.89% (n = 5), respectively.
Additional, internal standards, C17:0 and C17:0 methyl ester,
were used to evaluate the extraction yields with matrix eﬀect,
which were 86.20 ± 3.87% (n = 3) and 82.09 ± 1.25% (n = 3).
All results indicated that the method for the comprehensive
proﬁling of NEFAs and EFAs was satisfactory.
Under the optimum analytical method, the metabolic pro-
ﬁles of EFA and NEFA from 78 DM-2 patients and 45 health
controls were obtained by GC/MS, respectively. The NEFA
proﬁles of DM-2 patients (Fig. 1A) and health controls
(Fig. 1B) have shown that plasma free fatty acids of diﬀerent
people were almost the same, while the concentrations were
diﬀerent. Qualitative identiﬁcation of these characteristic con-
stituents was performed using retention times and mass spec-
tra. Among the twenty detected fatty acids, six components,
C16:1n-7, C18:1n-9, C18:1n-7, C18:2n-6, C18:3n-3 and
C18:3n-6, were unequivocally determined by the correspond-
ing standards according to their retention times and mass spec-
tra. The other components were tentatively identiﬁed in
chromatograms based on their electron bomb ionization (EI)
MS data. Qualitative results were also shown in Fig. 1. Be-
cause the mass spectra of double-bond positional isomersand geometrical isomers are almost the same, some compo-
nents which have isomers can not be identiﬁed in this experi-
ment, such as C20:3, C22:5.
The obtained NEFA and EFA proﬁles have illustrated that
the concentrations of fatty acids existed some diﬀerences be-
tween DM-2 patients and controls. However, because of the
inter-human variation in plasma matrix composition and
the complexity of the total ion chromatograms (TICs), cou-
pled with diﬀerences in the content of fatty acids, visual com-
parison of those fatty acid proﬁles is very diﬃcult. Hence,
chemometric methods of multivariate statistical analysis were
employed.3.2. PCA of GC/MS data
First of all, each fraction of fatty acids was analyzed using
PCA. Two scores plots of PC1 versus PC2, for NEFA and
EFA proﬁles, showed separation between 78 DM-2 patients
and 45 health controls. From Fig. 2, it is concluded that
PCA analysis poorly distinguished between the DM-2 patients
and health controls using NEFA proﬁles or EFA proﬁles. The
two groups were scattered. However, when the variables were
screened with the variable weight, much improvement was ob-
served in the separation between two groups for NEFA pro-
ﬁles with 87.80% correct rate (Fig. 3). PCA, an unsupervised
multivariate data analysis approach, is appropriate when it is
believed that a function of many attributes is involved in diﬀer-
ences between samples. However, the excessive irrelevant vari-
ables could result in confusion during the discrimination of
samples [23,28]. For EFA proﬁles, the two groups were still
scattered and could not be separated. The results indicated
that EFAs might not reﬂect diﬀerences between DM-2 patients
and controls, while the free fatty acids were suitable for classi-
ﬁcation. EFAs are from triglycerides, phospholipids, choles-
terol esters and so on. This kind of fatty acids is relatively
inactive. They are the stores of NEFA and will be released
and turned into NEFAs. So, the alterations of NEFA should
be the focus of our research. In the next PLS-LDA part, only
NEFA proﬁles were taken into account.3.3. The PLS-LDA model for discrimination of DM-2 and
health controls
In the present study, we aimed to construct a model to visu-
ally discriminate type 2 diabetic patients and health controls
and represent the variance of NEFA metabolic proﬁles of
DM-2 patients in the therapeutic process with rosiglitazone.
After overviewed the distribution of samples in the variable
space by PCA, the supervised method, PLS-LDA was pro-
posed to establish a visual model for the discrimination of
DM-2 patients and controls. Here, linear discrimination anal-
ysis (LDA) was employed to construct the discriminate plane
between two classes in the three-dimensional (3D) space.
Variable scaling is an integral part of PLS-LDA as it regu-
lates the relative importance of each variable in the subse-
quent model [29]. Autoscaling and centering are two widely
used variable scaling methods [30,31]. Autoscaling not only
centers the data set but also makes the standard variation
of variable to be the same units. The separation and predic-
tion ability of PLS-LDA model could be improved progres-
sively from using just centering, after the application of
autoscaling to the data set. The classiﬁcation results are
shown in Table 2. From Table 2 it can be seen that the
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Fig. 1. GC–MS proﬁles of free fatty acid methyl esters from plasma of the DM-2 patients (A) and health controls (B). (A) and (B) are the
chromatograms of FAMEs obtained by the optimum reaction condition and GC–MS condition. Those samples are derivatized and extracted from
plasma of DM-2 patients and health controls, respectively. Furthermore, the qualitative results were marked in (A). Components in (A) could also be
found in (B) sub-ﬁgures according to their retention times and mass spectra.
6840 L.-Z. Yi et al. / FEBS Letters 580 (2006) 6837–6845centered model showed relatively poor predictive ability with
76.67% prediction rate. The autoscaling model produced the
higher prediction rate (83.33%). Additionally, the recognition
rate (89.25%) and correct rate (87.80%) were both higher than
those of the centered model (83.87% and 82.11%, respec-
tively). In conclusion, the autoscaling method obviously
improved the performance of PLS-LDA pattern recogni-
tion analysis and enhanced the predictive power of themodel and was a good choice to optimize the class
separation.
To construct a stable and credible model, 10 validation PLS-
LDA models were calculated. Approximately three-fourths of
the samples (the ‘‘training set’’) were selected at random to
construct a PLS-LDA model that could be used to predict
the class membership of the remaining one-fourth of samples
(the ‘‘test set’’). After comparison, the ﬁnal 3D model of
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Fig. 2. PC scores plots derived from the total ion chromatograms (TIC) obtained from 78 DM-2 patients and 45 health controls before feature
selection. Key: d = health controls; } = DM-2 patients. (A) PC scores plots from TICs of NEFAs and (B) from TICs of EFAs. All data were
autoscaled.
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Fig. 3. PC scores plots of NEFAs generated from application of variable weight feature selection method to extract the informative variables. Key:
d = health controls; s = DM-2 patients.
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Fig. 4. 3D-projection plots of NEFAs from PLS-LDA of the ﬁrst
three latent variables (LV1, LV2 and LV3) for the 123 human plasma
samples. The discrimination plane between DM-2 patients and
controls was obtained by linear discrimination analysis (LDA). Key:
d = training set of controls; r = training set of DM-2 patients;
s = test set of controls; } = test set of DM-2 patients.
Table 2
Classiﬁcation of DM-2 patients and control samples by PLS-LDAa method
Method Recognition rate Prediction rate Sensitivity Speciﬁcity Correct rate
Centering 83.87% 76.67% 80.00% 83.33% 82.11%
78/93 23/30 36/45 65/78 101/123
Autoscaling 89.25% 83.33% 86.67% 88.46% 87.80%
83/93 25/30 39/45 69/78 108/123
aRecognition rate is the correct classiﬁcation of the training set. Prediction rate is the rate of the correct classiﬁcation of the test set. Sensitivity is the
number of true positives classiﬁed as positive. Speciﬁcity is the number of true negative classiﬁed as negative.
6842 L.-Z. Yi et al. / FEBS Letters 580 (2006) 6837–6845PLS-LDA was obtained which shown in Fig. 4. Samples of the
test set (the hollow circles and diamonds in Fig. 4) were homo-
geneously distributed in the 3D space obtained by the ﬁrst
three LVs. The DM-2 and controls were separated clearly by
the discriminate plane in both the training and test sets. The
equation of the discrimination plane was:
1:0t1 þ 1:167t2 þ 0:522t3 þ 1:108 ¼ 0 ð7Þ
where t1, t2, and t3 were the ﬁrst three LVs from PLS decom-
position.
In conclusion, the eﬃcient three dimensional visual model
has been successfully constructed using feature selection, auto-
scaling and PLS-LDA.
3.4. Alterations of NEFA metabolic proﬁles of type 2 diabetic
patients treated with rosiglitazone
Some publications have concluded that the total plasma
NEFA levels would be signiﬁcant lowered by rosiglitazone
and other TZDs, none of them reported the metabolic free
fatty acid proﬁles change track in long-term treatment
[32,33]. In the present research, 10 obese type 2 diabetic pa-
tients, including six women and four men, were treated with
rosiglitazone for about three months. Rosiglitazone is a hyper-
glycemic agent that works to lower the resistance to insulin in
fat, liver and muscle cells and also by stopping abnormalities
and dysfunctions in b-cells [24]. Herein, the constructed visualPLS-LDA model was employed to represent the variance of
NEFA metabolic proﬁles in the therapeutic process. Thirty
six NEFA metabolic proﬁles obtained by GC/MS were pro-
jected to the 3D space of PLS-LDA model. Fig. 5 represented
the time-dependent alterations in the levels of free fatty acids
following rosiglitazone treatment. Though the change tracks
of every patient were not the same, there was a subtle but pro-
gressive trend to the discriminate plane between DM-2 and
controls. There was an interesting phenomena demonstrated
in Fig. 5. For most patients, such as s1, s3, s4, the plasma
NEFA level increased after treated for two weeks. After that,
the plasma NEFA level decreased obviously. It indicated that
rosiglitazone does not lower plasma NEFA levels directly. The
pathogenesis of DM-2 is very complicated. For diﬀerent pa-
tients, their change tracks of free fatty acid metabolic proﬁles
maybe have some diﬀerences, such as patient s6 and s7. The
ﬁrst two months, plasma NEFA levels of these two patients de-
creased just as other patients. While, at the third month, their
plasma NEFA levels increased some. It inferred that the lipid
metabolism of these two patients has some diﬀerences with
others. This information will be very helpful for pathogenesis
research of diﬀerent people group in the future.
The 3D visual model showed us the plasma NEFA meta-
bolic proﬁles change track of every patient clearly. The results
further validated the eﬃciently of PLS-LDA model. It can not
only discriminate the DM-2 and controls, but also represent
the dynamic change track of NEFA proﬁles of patients after
treated with medicine. This method provided a powerful tool
for monitoring pharmacologic therapy, and will be a comple-
ment or an alternative to pathogenesis and pharmacodynamics
research.
3.5. Potential biomarkers
The 3D PLS-LDA model was obtained by nine variables
(C14:0, C16:0, C16:1n-9, C18:0, C18:1n-9, C18:1n-7, C20:3,
C24:0, total NEFAs) screening with variance weight. Those nine
variables have stronger inﬂuence than others for separation be-
tweenDM-2 and controls. It is a crude screening of variables. In
order to ﬁnd out the key NEFAs which contribute to the dis-
crimination of DM-2 and controls, say potential biomarkers,
further screening among those nine variables have been taken.
In this study, the equation of the discrimination plane ex-
pressed by PLS LVs (Eq. (7)) was transformed to that ex-
pressed by original variables. In the transformed equation
(Eq. (6)), the inﬂuence of original variables was represented
by the absolute values of coeﬃcients (b in Eq. (6)). So, the
compounds corresponding to these variables might be likely
candidates of biomarkers. Herein, absolute values of coeﬃ-
cients of the nine variables are shown in Fig. 6. The coeﬃcients
of C16:0, C18:0 and C18:1n-9 were obviously higher than
other fatty acids. Those three components might be the poten-
Fig. 5. 3D-projection plots of 36 samples from 10 DM-2 patients collected at 0 (n = 10), 2(n = 5), 4(n = 7), 9(n = 8) and 14 weeks (n = 6) after treated
with rosiglitazone. The change tracks of ten DM-2 patients were mapped separately in (A)–(J). Those samples were projected to the 3D space
obtained by PLS-LDA model. Key: } = DM-2 patients before treated (o week); d = 2 weeks; r = 4 weeks; s = 9 weeks; h = 14 weeks.
L.-Z. Yi et al. / FEBS Letters 580 (2006) 6837–6845 6843tial biomarkers, which were ﬁrstly identiﬁed for discrimination
DM-2 patients and health controls. Total NEFAs is the sum of
the twenty detected NEFAs. In clinic, total NEFAs is an
important index for diagnosis of DM-2. However, the absolutevalue of coeﬃcient of total NEFAs was clearly lower than the
three identiﬁed biomarkers. It inferred that using C16:0, C18:0
and C18:1n-9 as indexes may have more accurate result than
total NEFAs in the diagnosis of DM-2.
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Fig. 6. Absolute value of coeﬃcient of each variable selected by variable weight feature selection method. The absolute values of coeﬃcients (b in Eq.
(6)) can render the inﬂuence of corresponding variables on separation between sample classes. In turn, these compounds corresponding to these
variables might be likely candidates for biomarkers.
6844 L.-Z. Yi et al. / FEBS Letters 580 (2006) 6837–6845DM-2 is characterized by two major defects: a dysregulation
of pancreatic hormone secretion and a decrease in insulin ac-
tion on target tissues (insulin resistance). The defects in insulin
action on target tissues are characterized by a decreased in
muscle glucose uptake and by an increased hepatic glucose
production. These abnormalities are related to several defects
in insulin signaling mechanisms and in several steps regulating
glucose metabolism (transport, key enzymes of glycogen syn-
thesis or of mitochondrial oxidation) [34]. High circulating
concentrations of NEFAs can amplify these postreceptors de-
fects. Acute elevation of plasma NEFAs is necessary for insu-
lin secretion. Chronic exposure to high levels of plasma
NEFAs, however, leads to apoptosis of b-cells (lipotoxicity)
[35,36] and is a major risk factor for cardiovascular disease
and sudden death in patients with insulin resistance [19].
The three potential biomarkers, C16:0 (palmitic acid), C18:0
(stearic acid) and C18:1n-9 (oleic acid), are all very important
bioactive molecules. They are not only the main energy source
as nutrients, but also signaling molecules in various cellular
processes. The long-term high level of these fatty acids in plas-
ma may have more contribution to lipotoxicity than other NE-
FAs for their great inﬂuence on discrimination between DM-2
and controls. Some literatures have reported their relationship
between insulin sensitivity, substrate oxidation, and so on [37–
39]. The mechanism how NEFAs promote insulin secretion is
not clearly understood, though one pathway has found out,
that long-chain NEFAs amplify the insulin secretion from pan-
creatic b-cells by activating GPR40 [40–42]. Further researches
should be done to ﬁnd out their metabolic pathways and inter-
action with protein or other small molecules. It will be very
helpful for pathogenesis research of DM-2 and ﬁnding new
drug target. The three identiﬁed potential biomarkers may be
the target components in the future mechanism research.4. Conclusions
In this paper, a new strategy, metabolomics, was ﬁrstly ap-
plied to research of dynamic plasma fatty acid metabolic pro-
ﬁling and biomarkers of DM-2. The application of GC/MS
coupled with PLS-LDA of data with variable weight scanningmakes it possible to classify DM-2 patients and health controls
and, further, to establish a 3D PLS-LDA model to visual rep-
resent alterations of NEFA metabolic proﬁles of type 2 dia-
betic patients treated with rosiglitazone for about 3 months.
Furthermore, we discovered the potential biomarkers which
could be identiﬁed by MS and corresponding standards.
The combination of multivariate approach and GC/MS
data-mining metabolite identiﬁcation program results in a very
powerful tool for metabolomics research. This work has illus-
trated the potential of metabolomics to disease diagnose, path-
ogenesis and pharmacodynamics research.Acknowledgements: This work is ﬁnancially supported by the National
Nature Foundation Committee of PR China (Grants No. 20235020
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technical Innovation project, Ministry of Education of China (No.
704036).References
[1] Oliver, S.G., Winson, M.K., Kell, D.B. and Baganz, F. (1998)
Systematic functional analysis of the yeast genome. Trends
Biotechnol. 16, 373–378.
[2] Sauter, H., Lauer, M. and Fritsch, H. (1991) Metabolic proﬁling
of plants – a new diagnostic technique. ACS. Symp. Ser. 443, 288–
299.
[3] Fiehn, O. (2002) Metabolomics – the link between genotype and
phenotype. Plant Mol. Biol. 48, 155–171.
[4] Weckwerth, W., Tolstikov, V. and Fiehn, O. (2001). Metabolomic
characterization of transgenic potato plants using GC/TOF and
LC/MS. Paper presented at the 49th ASMS Conference on Mass
spectrometry and Allied Topics.
[5] Taylor, J., Ross, D.K., Thomas, A. and Fiehn, O. (2002)
Application of metabolomics to plant genotype discrimination
using statistics and machine learning. Bioinformatics 18, 241–248.
[6] Nicholson, J.K., Connelly, J., Lindon, J.C. and Holmes, E. (2002)
Metabonomics: a platform for studying drug toxicity and gene
function. Nat. Rev. 1, 153–161.
[7] Chen, M. and Hofestadt, R. (2006) A medical bioinformatics
approach for metabolic disorders: Biomedical data prediction,
modeling, and systematic analysis. J. Biomed. Inform. 39, 147–
159.
[8] Dunckley, T., Coon, K.D. and Stephan, D.A. (2005) Discovery
and development of biomarkers of neurological disease. Drug
Discov Today 10, 326–334.
L.-Z. Yi et al. / FEBS Letters 580 (2006) 6837–6845 6845[9] Barshop, B.A. (2004) Metabolomic approaches to mitochondrial
disease: correlation of urine organic acids. Mitochondrion 4, 521–
527.
[10] Griﬃn, J.L. (2003) Metabonomics: NMR spectroscopy and
pattern recognition analysis of body ﬂuids and tissues for
characterisation of xenobiotic toxicity and disease diagnosis.
Curr. Opin. Chem. Biol. 7, 648–654.
[11] Griﬃn, J.L., Mann, C.J., Scott, J., Shoulders, C.C. and Nichol-
son, J.K. (2001) Choline containing metabolites during cell
transfection: an insight into magnetic resonance spectroscopy
detectable changes. FEBS Lett. 509, 263–266.
[12] Griﬃn, J.L., Anthony, D.C., Campbell, S.J., Gauldie, J., Pitossi,
F., Styles, P. and Sibson, N.R. (2004) Study of cytokine induced
neuropathology by high resolution proton NMR spectroscopy of
rat urine. FEBS Lett. 568, 49–54.
[13] Arani’bar, N., Ott, K.-H., Roongta, V. and Mueller, L. (2006)
Metabolomic analysis using optimized NMR and statistical
methods. Anal. Biochem. 355, 62–70.
[14] Samuelsson, L.M., Forlin, L., Karlsson, G., Adolfsson-Erici, M.
and Larsson, D.G.J. (2006) Using NMR metabolomics to identify
responses of an environmental estrogen in blood plasma of ﬁsh.
Aqua. Toxicol. 78, 341–349.
[15] Stumvoll, M., Goldstein, B.J. and Haeften, T.W.v. (2005) Type 2
diabetes: principles of pathogenesis and therapy. Lancet 365,
1333–1346.
[16] Bergman, R.N. and Ader, M. (2000) Free fatty acids and
pathogenesis of type 2 diabetes mellitus. Trends Endocrinol
Metabol. 11, 351–356.
[17] Suresh, Y. and Das, U.N. (2003) Long-chain polyunsaturated
fatty acids and chemically induced diabetes mellitus: eﬀect of
[omega]-3 fatty acids. Nutrition 19, 213–228.
[18] Suresh, Y. and Das, U.N. (2003) Long-chain polyunsaturated
fatty acids and chemically induced diabetes mellitus: eﬀect of
[omega]-6 fatty acids. Nutrition 19, 93–114.
[19] Wyne, K.L. (2003) Free fatty acids and type 2 diabetes mellitus.
Am. J. Med. 115, 29–36.
[20] Boden, G. (1999) Free fatty acids, insulin resistance, and type 2
diabetes mellitus. Proc. Assoc. Am. Phys. 3, 241–248.
[21] Boden, G. and Chen, X. (1995) Eﬀects of fat on glucose uptake
and utilization in patients with non-insulin-dependent diabetes. J.
Clin. Invest. 96, 1261–1268.
[22] Reaven, G.M. and Chen, Y.D. (1988) Role of abnormal free fatty
acid metabolism in the development of non-insulin dependent
diabetes mellitus. Am. J. Med. 85 (Suppl. 5A), 106–113.
[23] Yang, J., Xu, G., Hong, Q., Liebich, H.M., Lutz, K., Schmulling,
R.M. and Wahl, H.G. (2004) Discrimination of type 2 diabetic
patients from healthy controls by using metabonomics method
based on their serum fatty acid proﬁles. J. Chromatogr. B 813,
53–58.
[24] Junga, H.S., Younb, B.-S., Choa, Y.M. and Yub, K.-Y. (2005)
The eﬀects of rosiglitazone and metformin on the plasma
concentrations of resistin in patients with type 2 diabetes mellitus.
Metabolism 54, 314–320.
[25] Harold, E.L. and Mary, A.B. (2004) Treatment of insulin
resistance in diabetes mellitus. Eur. J. Pharmacol. 490, 135–146.
[26] Racette, S.B., Davis, A.O., McGill, J.B. and Klein, S. (2002)
Thiazolidinediones enhance insulin-mediated suppression of fatty
acid ﬂux in type 2 diabetes mellitus. Metabolism 51, 169–174.[27] Xu, Q.S., Liang, Y.Z. and Shen, H.L. (2001) Gernalized PLS
regression. J. Chemometr. 15, 135–148.
[28] Wang, C., Kong, H.W., Guan, Y.F., Yang, J., Gu, J.R., Yang,
S.L. and Xu, G.W. (2005) plasma phospholipid metabolic
proﬁling and biomarkers of type 2 diabetes mellitus based on
high-performance liquid chromatography/electrospray mass spec-
trometry and multivariate statistical analysis. Anal. Chem. 77,
4108–4116.
[29] Hsu, F.F. and Turk, J. (2000) Characterization of phosphatidyl-
ethanolamine molecular species as Li+ adducts. by triple quad-
rupole tandem mass spectrometry with electrospray ionization. J.
Mass Spectrom. 35, 596–606.
[30] Bro, R. and Smilde, A.K. (2003) Centering and scaling in
component analysis. J. Chemometr. 17, 16–33.
[31] Paatero, P. and Hopke, P.K. (2003) Discarding or downweighting
high-noise variables in factor analytic models. Anal. Chim. Acta
490, 277–289.
[32] Tan, G.D., Fielding, B.A., Currie, J.M., Humphreys, S.M.,
Desage, M., Frayn, K.N., Laville, M., Vida, I.H. and Karpe, F.
(2005) The eﬀects of rosiglitazone on fatty acid and triglyceride
metabolism in type 2 diabetes. Diabetologia 48, 6–7.
[33] Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K.,
Mahankali, A., Mahankal, S.I., Mandarino, L.J. and DeFronzo,
R.A. (2001) Eﬀect of rosiglitazone on glucose and non-esteriﬁed
fatty acid metabolism in type II diabetic patients. Diabetologia
44, 2210–2219.
[34] Girard, J. (2005) Contribution of free fatty acids to impairment of
insulin secretion and action mechanism of b-cell lipotoxicity.
Med. Sci. (Paris) 21, 19–25.
[35] Cnop, M., Hannaert, J.C., Hoorens, A., Eizirik, D.L. and
Pipeleers, D.G. (2001) Inverse relationship between cytotoxicity
of free fatty acids in pancreatic islet cells and cellular triglyceride
accumulation. Diabetes 50, 1771–1777.
[36] Weinberg, J.M. (2006) Lipotoxicity. Kidney Int. 70, 1560–1566.
[37] Lovejoy, J.C., Smith, S.R., Champagne, C.M., Most, M.M.,
Lefevre, M., DeLany, J.P., Denkins, Y.M., Rood, J.C., Veldhuis,
J. and Bray, G.A. (2002) Eﬀects of diets enriched in saturated
(Palmitic), monounsaturated (Oleic), or trans (Elaidic) fatty acids
on insulin sensitivity and substrate oxidation in healthy adults.
Diabetes Care 25, 1283–1288.
[38] Wang, X.L., Zhang, L., Youker, K., Zhang, M.X., Wang, J.,
Lemaire, S.A., Coselli, J.S. and Shen, Y.H. (2006) Free fatty acids
inhibit insulin signaling-stimulated endothelial nitric oxide syn-
thase activation through upregulating PTEN or inhibiting Akt
kinase. Diabetes 55, 2301–2310.
[39] Sauma, L., Stenkula, K.G., Kjolhede, P., Stralfors, P., Soder-
strom, M. and Nystrom, F.H. (2006) PPAR-gamma response
element activity in intact primary human adipocytes: eﬀects of
fatty acids. Nutrition 22, 60–68.
[40] Itoh, Y., Kawamata, Y.J. and Harada, M., et al. (2003) Free fatty
acids regulate insulin secretion from pancreatic b cells through
GPR40. Nature 422, 173–176.
[41] Chalmers, D.T. and Behan, D.P. (2002) The use of constitutively
active GPCRs in drug discovery and functional genomics. Nat.
Rev. Drug Discov. 1, 599–608.
[42] Saltiel, A.R. and Kahn, C.R. (2001) Insulin signalling and
the regulation of glucose and lipid metabolism. Nature 414,
799–806.
